1 min read
Add as a preferred source on Google

SELLAS Life Sciences Group Begins $150 Million Stock Offering

The company plans to grant underwriters a 30-day option to buy additional shares.

A blank share certificate rests beside a glass microscope slide / TokenPost.ai (macro)
A blank share certificate rests beside a glass microscope slide / TokenPost.ai (macro)

SELLAS Life Sciences Group, Inc. (SLS) began an underwritten $150 million public offering of common stock Tuesday, Nov. 17, and plans to grant underwriters a 30-day option to purchase additional shares.

The offering follows positive results from REGAL, the company’s Phase 3 trial involving patients with acute myeloid leukemia. SLS shares rose more than 281% after the trial results. The trial showed a statistically significant improvement in overall survival.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…